title: Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
authors: Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. breccia@bce.uniroma1.it
authors: Massimo
authors: M
authors: Breccia
authors: Fabio
authors: F
authors: Stagno
authors: Antonella
authors: A
authors: Gozzini
authors: Elisabetta
authors: E
authors: Abruzzese
authors: Roberto
authors: R
authors: Latagliata
authors: Antonella Russo
authors: AR
authors: Rossi
authors: Federica
authors: F
authors: Sorà
authors: Raffaele
authors: R
authors: Porrini
authors: Paolo
authors: P
authors: Vigneri
authors: Malgorzata
authors: M
authors: Trawinska
authors: Enrico
authors: E
authors: Montefusco
authors: Simona
authors: S
authors: Sica
authors: Giorgina
authors: G
authors: Specchia
authors: Valeria
authors: V
authors: Santini
authors: Giuliana
authors: G
authors: Alimena